OpGen shows profitable future merging with Curetis NV
OpGen Inc(OPGN) currently trades at $2.94 and has grown 6.52% in the past 24 hours. Quorum achieved for OpGen stockholder vote on Curetis business combination with 99% of votes supporting transaction. Combined OpGen and Curetis business generated $6 million in unaudited pro forma combined 2019 revenue (up from $4.5 million in 2018).
Based on this information, investorsQ rates this stock a 5 out of 10. We give it this rating because First shipments of BGI SARS-CoV-2 rapid PCR kits completed by Curetis in Europe. Additional actions planned to address the global COVID-19 pandemic.. The high forecast for OpGen Inc is $2.50 and the low is $2.50. Notably, the company’s market cap is $35.07 million with a 52 week high of $15.20 and a 52 week low of $0.92.